ASCO 2025: Cost Savings and Clinical Outcomes of Pre-Treatment DPYD Genotyping Before Fluoropyrimidine Therapy

by MM360 Staff | May 28, 2025 | Myeloma News | 0 comments

Source: Pharmacy Times articles

Pre-treatment DPYD genotyping significantly reduces hospitalizations and costs for patients with cancer, enhancing safety and efficiency in oncology care.
Read More

Submit a Comment Cancel reply

You must be logged in to post a comment.

ASCO 2025: Cost Savings and Clinical Outcomes of Pre-Treatment DPYD Genotyping Before Fluoropyrimidine Therapy

Submit a Comment Cancel reply

Recent Content